CD274 and non-small cell lung carcinoma: In locally advanced unresectable NSCLC, immunotherapy, particularly PD-L1 inhibitors like durvalumab, has shown remarkable efficacy as consolidation therapy after chemotherapy and radiotherapy, demonstrating prolonged OS by suppressing inhibitory molecules in the TME and inducing antitumor immune responses (151).